Douglas K. Spracklin

Author

Also Known As

D K Spracklin, D. K. SPRACKLIN, D. K. Spracklin, Douglas K. Spracklin, Spracklin, Douglas K., Spracklin, Douglas Kenneth

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Washington

About

Douglas K. Spracklin is an author at Pfizer (United States) specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	237
2	Biochemistry	4	4	89
3	Natural Sciences	3	3	89
4	Social Sciences	2	2	117
5	Anesthesia	1	1	15

Douglas K. Spracklin

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL Angela C. Doran, R. Scott Obach, Bill J. Smith, Drug Metabolism and Disposition	2004	440
Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139 Thomas A. Lanz, Michael J. Karmilowicz, Kathleen M. Wood, Journal of Pharmacology and Experimental Therapeutics	2006	133
Cytochrome P450 2E1 is the Principal Catalyst of Human Oxidative Halothane Metabolism in Vitro Douglas K. Spracklin, Douglas C. Hankins, Jeannine M. Fisher, Journal of Pharmacology and Experimental Therapeutics	1997	121
Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs Raman Sharma, Timothy J. Strelevitz, Hongying Gao, Drug Metabolism and Disposition	2011	112
Discovery of Two Clinical Histamine H <sub>3</sub> Receptor Antagonists: <i>trans</i> - <i>N</i> -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and <i>trans</i> -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- <i>N</i> -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764) Travis T. Wager, Betty Pettersen, Anne W. Schmidt, Journal of Medicinal Chemistry	2011	107
Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation Yvette E. Savoy, Michael A. Ashton, M. W. Miller, Schizophrenia Bulletin Psychotropic MedicationPsychopharmacologyPharmacotherapyInsulin LevelsSocial Sciences	2008	74
Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk, Journal of Medicinal Chemistry	2009	73
Biosynthesis of Drug Metabolites and Quantitation Using NMR Spectroscopy for Use in Pharmacologic and Drug Metabolism Studies Gregory S. Walker, Jonathan Bauman, Tim F. Ryder, Drug Metabolism and Disposition	2014	63
Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Douglas K. Spracklin, Kenneth E. Thummel, Evan D. Kharasch Drug Metabolism and Disposition	1996	55
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release David E. Johnson, Frank M. Nedza, Douglas K. Spracklin, European Journal of Pharmacology PsychiatryMedicineSynaptic TransmissionPsychotropic MedicationNeurotransmitter	2004	43

Page 1